贝叶斯式方法使得多个人类iPSC衍生的心肌细胞的心律失常敏感度的客观比较成为可能
Tetsuro Wakatsuki1, Neil Daily2, Sunao Hisada3
1Consortium for Safety Assessment Using Human iPS Cells (CSAHi), HEART Team, Tokyo, Japan; InvivoSciences, Inc., Madison, WI 53719, USA.
Journal of pharmacological and toxicological methods
|June 9, 2024
概括
这项研究开发了使用人类心脏细胞评估药物诱导心律问题的新方法. 这些发现有助于通过分析细胞行为和离子通道效应,更好地预测药物安全性.
科学领域:
- 心血管药理学心血管药理学
- 药物安全评估 药物安全评估
- 干细胞技术 干细胞技术
背景情况:
- 传统医学使用一种适合所有人的方法,而精准医学则针对特定的患者群体.
- 计算模型有助于预测药物诱导的前节律失常风险 in silico.
- 在实验安全药理学中,人口建模存在挑战.
研究的目的:
- 开发和验证用于评估人类诱导多能干细胞衍生心肌细胞 (hiPSC-CMs) 中化合物诱导的前节律失常风险的新方法.
- 描述和比较不同hiPSC-CM细胞系对各种化合物的前节律敏感性.
- 为了客观地评估药物安全性,将表型数据与离子通道抑制结合起来.
主要方法:
- 在384个井板中利用了五个人类iPSC-CM细胞系,以测试四种度的十种前节律性化合物.
- 分析过渡 (CaTs) 并定义了六个参数来描述波形变化和节拍不规则.
- 采用贝叶斯统计数据进行人口预测和主要成分分析,以客观地分类化合物诱导的敏感性.
主要成果:
- 所有细胞系都显示了CaT持续时间的化合物依赖性变化,其中一些细胞系表现出模拟无法预测的不规则跳动.
- 新的参数有效地可视化和差异化跨细胞系的化合物诱导的前节律敏感性.
- 贝叶斯统计和主要成分分析使细胞系敏感性的客观分类成为可能.
结论:
- 开发的表型参数和统计方法为评估高PSC-CMs中药物诱导的前节律失常风险提供了可靠的方法.
- 这种方法克服了高通量测定中的实验复制物的局限性,并有助于客观地评估药物安全性.
- 这些发现有助于推进个性化医疗,并改善药物诱导的心脏不良事件的预测.
关键词:
贝叶斯语 贝叶斯语 贝叶斯语 贝叶斯语心脏安全性心脏安全性一个心肌细胞.计算建模计算建模数据科学是数据科学.高通量的高通量.图像成像是一种成像.方法 方法 方法个性化医疗是个性化的医疗.预节律失常症 预节律失常症更多相关视频
08:53Human iPSC-Derived Cardiomyocyte Networks on Multiwell Micro-electrode Arrays for Recurrent Action Potential Recordings
Published on: July 15, 2019
11.6K
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
1.8K
相关概念视频
Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...
Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...
iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
